ZappRx, Inc., a Boston, MA-based digital health company focused on expediting the specialty drug prescribing process, closed a $25m Series B funding round.
The round was led by Qiming US Healthcare Fund, a venture capital firm based in Seattle that is part of Qiming Venture Partners, with participation from SR One and GV (formerly Google Ventures). As part of the financing, Mark McDade, Managing Partner at Qiming US, will join ZappRx’s Board of Directors.
This investment will help accelerate commercialization of its product to academic medical centers and large multi-specialty practices in the US.
Led by Founder and CEO Zoë Barry, ZappRx provides a cloud-based collaborative platform that allows patients, physicians and pharmacists to work together to improve access to treatment, enabling providers who treat complex conditions in categories like oncology, pulmonology, rheumatology, neurology and gastroenterology to focus more on patient care delivering medicine faster and less on the paperwork required for getting patients on therapy.